- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04673357
En studie av Ustekinumab hos pediatriske deltakere med moderat til alvorlig aktiv Crohns sykdom (UNITI Jr)
2. juli 2026 oppdatert av: Janssen Research & Development, LLC
En fase 3-studie av effekten, sikkerheten og farmakokinetikken til Ustekinumab som åpen intravenøs induksjonsbehandling etterfulgt av randomisert dobbeltblind subkutan Ustekinumab-vedlikehold hos pediatriske deltakere med moderat til alvorlig aktiv Crohns sykdom
Hensikten med denne studien er å evaluere effekten av ustekinumab-dosering for å indusere klinisk remisjon (global) og opprettholde klinisk remisjon (US); for å evaluere sikkerhetsprofilen og ustekinumab eksponering (farmakokinetikk [PK]) hos pediatriske deltakere med moderat til alvorlig aktiv Crohns sykdom.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
101
Fase
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Brussels, Belgia, 1200
- Cliniques Universitaires Saint Luc
-
Brussels, Belgia, 1020
- Universitair Kinderziekenhuis Koningin Fabiola
-
Ghent, Belgia, 9000
- UZ Gent
-
Jette, Belgia, 1090
- UZ Brussel
-
Leuven, Belgia, 3000
- UZ Leuven
-
-
-
-
Delaware
-
Wilmington, Delaware, Forente stater, 19803
- Nemours DuPont Hospital for Children
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30342
- Children's Center for Digestive Health Care
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Mayo Clinic
-
-
New Jersey
-
Morristown, New Jersey, Forente stater, 07962
- Morristown Memorial Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28207
- Levine Childrens at Atrium Health
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44106
- University Hospitals Cleveland Medical Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, Forente stater, 17033
- Penn State Hershey Children's Hospital
-
-
Texas
-
Fort Worth, Texas, Forente stater, 76104
- Cook Childrens Medical Center
-
-
Virginia
-
Fairfax, Virginia, Forente stater, 22031
- Pediatric Specialists Of Virginia
-
-
-
-
-
Be’er Ya‘aqov, Israel, 70300
- Yitzhak Shamir Medical Center
-
Haifa, Israel, 34362
- Carmel Medical Center
-
Jerusalem, Israel, 9103102
- Shaare Zedek Medical Center
-
Petah Tikva, Israel, 4920235
- Schneider Children's Medical Center
-
-
-
-
-
Bunkyō City, Japan, 113 8431
- Juntendo University Hospital
-
Gunma, Japan, 371-0034
- Gunma University Hospital
-
Ikoma, Japan, 630-0293
- Kindai University Nara Hospital
-
Kurume, Japan, 830-0011
- Kurume University Hospital
-
Saitama Shi, Japan, 330-8777
- Saitama Childrens Medical Center
-
Sendai, Japan, 989-3126
- Miyagi Children's Hospital
-
Setagaya Ku, Japan, 157 8535
- National Center for Child Health and Development
-
Shimotsuke, Japan, 329-0498
- Jichi Medical University Hospital
-
Tsu, Japan, 514 8507
- Mie University Hospital
-
-
-
-
-
Gdansk, Polen, 80 803
- Szpital im. M. Kopernika
-
Krakow, Polen, 30 663
- Uniwersytecki Szpital Dzieciecy w Krakowie
-
Rzeszów, Polen, 35-302
- Korczowski Bartosz Gabinet Lekarski
-
Warsaw, Polen, 04 501
- WIP Warsaw IBD Point Profesor Kierkus
-
Warsaw, Polen, 04 730
- Instytut Pomnik Centrum Zdrowia Dziecka
-
-
-
-
-
Kazan', Russland, 420138
- Kazan State Medical University
-
Moscow, Russland, 119571
- Russian National Research Medical University named after N.I.Pirogov
-
Nizhny Novgorod, Russland, 603950
- Privolzhsky Research Medical University of Ministry of Health of Russian Federation
-
Yaroslavl, Russland, 150032
- Yaroslavl Regional Children's Clinical Hospital
-
-
-
-
-
Birmingham, Storbritannia, B4 6NH
- Birmingham Children's Hospital
-
Bristol, Storbritannia, BS2 8BJ
- University Hospitals Bristol and Weston NHS Foundation Trust
-
Cambridge, Storbritannia, CB2 0QQ
- Cambridge University Hospitals NHS Foundation Trust
-
Edinburgh, Storbritannia, EH16 4TJ
- Royal Hospital for Children and Young People
-
London, Storbritannia, E1 2AT
- Royal London Hospital
-
-
-
-
-
Aachen, Tyskland, 52074
- Universitätsklinikum Aachen
-
Berlin, Tyskland, 13353
- Charite-Universitätsmedizin Berlin - Berlin
-
Essen, Tyskland, 45147
- Universitätsklinikum Essen
-
Hanover, Tyskland, 30625
- Medizinische Hochschule Hannover
-
Munich, Tyskland, 80337
- Dr. von Haunersches Kinderspital
-
Regensburg, Tyskland, 93049
- KUNO Klinik St. Hedwig
-
Ulm, Tyskland, 89075
- Universitätsklinikum Ulm
-
-
-
-
-
Budapest, Ungarn, 1083
- Semmelweis Egyetem
-
Debrecen, Ungarn, 4032
- Debreceni Egyetem Klinikai Kozpont
-
Miskolc, Ungarn, 3526
- Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz
-
Nyíregyháza, Ungarn, 4400
- Szabolcs Szatmár Bereg Vármegyei Oktatókórház
-
Szeged, Ungarn, 6720
- Szegedi Tudományegyetem, Gyermekgyógyászati Klinika és Gyermekegészségügyi Centrum
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
2 år til 17 år (Barn)
Tar imot friske frivillige
Nei
Beskrivelse
Inklusjonskriterier:
- Har Crohns sykdom eller fistulerende Crohns sykdom med aktiv kolitt, ileitt eller ileokolitt, bekreftet til enhver tid tidligere ved endoskopi og histologi
- Må ha moderat til alvorlig aktiv Crohns sykdom (som definert av en baseline Pediatric Crohns Disease Activity Index [PCDAI]-score større enn [>] 30); ha ileokolonoskopi med bevis på aktiv Crohns sykdom definert som tilstedeværelse av sårdannelse (som er lik Simple Endoscopic Score for Crohns sykdom [SES-CD]-score større enn eller lik [>=] 3) under screening i denne studien. Ileokolonoskopi-prosedyren må finne sted innen ca. 3 uker før administrasjon av studieintervensjon ved uke 0 (induksjonsperiode). En video-ileokolonoskopi tatt opp innen 3 måneder før besøket i uke 0 (induksjonsperiode) kan brukes i tilfelle rescreening av en deltaker som hadde en ileokolonoskopi, men som mislyktes i den første screeningen av en annen grunn, fra sak til sak, etter konsultasjon med sponsor. Hvis du ikke er i stand til å evaluere sårdannelse på grunn av striktur eller utilstrekkelig tarmforberedelse, kan minst ett av følgende kriterier brukes i stedet: et unormalt C-reaktivt protein (CRP) (> 0,3 milligram per desiliter [mg/dL] eller 3,0 milligram per liter [mg/L] ved screening) eller; fekalt kalprotektin på >= 250 milligram per kilogram [mg/kg] eller >= 250 mikrogram per gram [mcg/g] ved screening
- Hvis du mottar enteral ernæring, må du ha vært på en stabil diett i minst 2 uker før induksjon uke 0 (uke I-0)
- Kvinner i fertil alder må ha en negativ svært sensitiv uringraviditetstest ved screening og ved uke I-0 før administrasjon av studieintervensjon
Ekskluderingskriterier:
- Har komplikasjoner av Crohns sykdom som symptomatiske strikturer eller stenose, kort tarmsyndrom eller andre manifestasjoner som kan forventes å kreve kirurgi, som kan utelukke bruk av PCDAI for å vurdere respons på terapi eller som muligens vil forvirre evnen til å vurdere effekt av behandling med ustekinumab
- Har en historie med latent eller aktiv granulomatøs infeksjon, histoplasmose eller coccidioidomycosis, eller har hatt en ikke-tuberkuløs mykobakteriell infeksjon før screening
- Tilstedeværelse eller historie med malignitet, inkludert tilstedeværelse eller historie med lymfoproliferativ sykdom inkludert lymfom, eller tegn og symptomer som tyder på mulig lymfoproliferativ sykdom, slik som lymfadenopati av uvanlig størrelse eller plassering (eksempel, noder i den bakre trekant av halsen, infraklavikulær, epitrokleær, eller periortiske områder), og monoklonal gammopati av ubestemt betydning, eller klinisk signifikant hepatomegali eller splenomegali
- Har en historie med moderat eller alvorlig progressiv eller ukontrollert lever- eller nyresvikt; eller betydelige hjerte-, vaskulære, pulmonale, gastrointestinale, endokrine, nevrologiske, hematologiske, psykiatriske (inkludert suicidalitet) eller metabolske forstyrrelser
- Mottatt en undersøkelsesintervensjon inkludert eventuelle undersøkelsesvaksiner eller brukt et invasivt undersøkelsesmedisinsk utstyr innen 3 måneder før den planlagte første dosen av studieintervensjon eller er for øyeblikket registrert i en undersøkelsesstudie; mottak av en undersøkelsesvaksine for Coronavirus Disease 2019 (COVID-19) er ikke et automatisk eksklusjonskriterium
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Open-Label Ustekinumab Intravenøs (IV): Induksjonsperiode
Alle deltakerne vil motta en enkelt IV-administrasjon av ustekinumab ved induksjonsuke 0 (I-0) basert på kroppsoverflateareal (BSA) (milligram per kvadratmeter kvadrat [mg/m^2]) eller vektdelt induksjonsdose (milligram per kilogram [mg/kg]).
|
Ustekinumab vil bli administrert intravenøst i induksjonsperioden og subkutant i vedlikeholdsperioden.
|
|
Eksperimentell: Ustekinumab subkutan (SC) hver 8. uke (q8w): Vedlikeholdsperiode
Deltakerne vil motta SC-administrasjon av ustekinumab q8w basert på BSA (mg/m^2) eller vektdelt induksjonsdose (mg/kg) ved vedlikeholdsuker (uker M)-0, M-8, M-16, M-24 , M 32 og M-40 og matchende placebo i uke M-12 og M-36 for å opprettholde blinden.
|
Ustekinumab vil bli administrert intravenøst i induksjonsperioden og subkutant i vedlikeholdsperioden.
Matchende placebo vil bli administrert som SC-injeksjon.
|
|
Eksperimentell: Ustekinumab SC hver 12. uke (q12w): Vedlikeholdsperiode
Deltakerne vil motta SC-administrasjon av ustekinumab q12w basert på BSA (mg/m^2) eller vektdelt induksjonsdose (mg/kg) i uke M-0, M-12, M-24, M-36 og matchende placebo kl. Uke M-8, M-16, M-32 og M-40 for å vedlikeholde blinden.
|
Ustekinumab vil bli administrert intravenøst i induksjonsperioden og subkutant i vedlikeholdsperioden.
Matchende placebo vil bli administrert som SC-injeksjon.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 8 (Week I-8)
Tidsramme: Induction Week 8 (Week I-8)
|
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10.
The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: hematocrit [HCT], erythrocyte sedimentation rate [ESR], Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations.
The category of severity for each index item is assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality.
For hematocrit and erythrocyte SR, the maximum score =5.
For albumin level, the maximum score = 10.
All items were summed to derive the total score.
The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
|
Induction Week 8 (Week I-8)
|
|
US-specific Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44
Tidsramme: Maintenance Week 44 (Study Week 52)
|
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10.
The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations.
The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality.
For hematocrit and erythrocyte SR, the maximum score= 5.
For albumin level, the maximum score= 10.
All items were summed to derive the total score.
The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
|
Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Tidsramme: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
Number of participants with TEAEs were reported.
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.
An AE did not necessarily have a causal relationship with the intervention.
TEAEs were defined as AEs occurring at or after the initial administration of the study intervention.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Tidsramme: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
Number of participants with TESAEs was reported.
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.
An AE did not necessarily have a causal relationship with the intervention.
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly.
TESAEs were defined as any SAE occurring at or after the initial administration of the study intervention.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Number of Participants With AEs Leading to Discontinuation of Study Intervention
Tidsramme: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
|
Number of participants with AEs leading to discontinuation of study intervention were reported.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
|
|
Global and US-specific Outcome Measures: Number of Participants With AEs of Special Interest (AESI)
Tidsramme: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.
An AE did not necessarily have a causal relationship with the intervention.
AESI were defined as any newly identified malignancy, or case of active TB, or opportunistic infection occurring after the first administration of study intervention.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology
Tidsramme: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
Number of participants with abnormalities in clinical laboratory parameters (hematology) were reported.
It included hemoglobin (Hb).
Grades 0-4 were based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), where Grade 0 was normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences.
Higher grades showed more severe abnormalities.
Only abnormalities where atleast one participant had data are reported.
Inc = increased, Dec= decreased.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Chemistry
Tidsramme: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
Number of participants with abnormalities in clinical laboratory parameters were reported.
It included chemistry measures: alanine aminotransferase (ALT), aspartate aminotransferase (AST),blood bilirubin (BB).
Grades 0-4 were based on NCI-CTCAE version 5.0, where Grade 0 was Normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences.
Higher grades showed more severe abnormalities.
Only abnormalities where at least one participant had data are reported.
Inc = increased, Dec= decreased.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)
Tidsramme: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
Number of participants with reactions temporally associated with intravenous (IV) infusion (Induction Period) and subcutaneous (SC) Injection-Site Reactions (Maintenance Period) were reported.
|
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
|
|
Global and US-specific Outcome Measures: Serum Ustekinumab Concentrations
Tidsramme: Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44
|
Serum ustekinumab concentrations were reported.
|
Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 6 as Assessed by Short Pediatric Crohn's Disease Activity Index (sPCDAI)
Tidsramme: Induction Week 6 (Week I-6)
|
Clinical remission was defined as a short Pediatric Crohn's Disease Activity Index (sPCDAI) score <=10.
The sPCDAI was composed of six components: abdominal pain, stool frequency, patient general well-being, body weight, abdominal examination (abdominal mass and tenderness), and extraintestinal manifestations.
Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected clinical remission or minimal disease activity.
Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90.
Higher score indicate greater severity.
The sPCDAI score was calculated only when >=3 of the 6 components were available.
|
Induction Week 6 (Week I-6)
|
|
Global Outcome Measure: Percentage of Participants With Clinical Response at Induction Week 8
Tidsramme: Induction Week 8
|
Assessment of response in children with Crohn's disease was evaluated using the PCDAI.
Clinical response was defined as a reduction from baseline of >=12.5 points in the PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history (abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores (weight and height); physical examination scores (abdominal and perirectal disease); and extraintestinal manifestations.
Each index item was assigned a severity score of 0 (normal), 5 (mild abnormality), or 10 (severe abnormality).
For HCT and ESR, maximum score was 5, and for albumin level, maximum score was 10.
The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Lower PCDAI scores reflected lower disease activity, with a resulting score of <=30 on the 0-100 scale.
|
Induction Week 8
|
|
Global and US-specific Outcome Measures: Percentage of Participants With Clinical Response at Induction Week 6 as Assessed by sPCDAI
Tidsramme: Induction Week 6
|
sPCDAI clinical response was defined as reduction from baseline in the sPCDAI score of >=10.
The 6-item sPCDAI score ranges from 0 (no disease activity) to 90 (severe disease activity),calculated by summing weighted scores for abdominal pain, stool frequency, general well-being, body weight, abdominal exam, and extraintestinal manifestations.
Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected minimal disease activity.
Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90.
Higher score indicate greater severity.
The sPCDAI score was only calculated when >=3 of the 6 components were available.
|
Induction Week 6
|
|
Global Outcome Measure: Percentage of Participants With Endoscopic Response at Maintenance Week 8 as Assessed by Simplified Endoscopic Score-Crohn's Disease (SES-CD)
Tidsramme: Maintenance Period Week 8 (Study Week 16)
|
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing.
Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum.
Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity.
Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
|
Maintenance Period Week 8 (Study Week 16)
|
|
Global Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 8
Tidsramme: Maintenance Week 8 (Study Week 16)
|
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations.
Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality).
For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10.
Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
|
Maintenance Week 8 (Study Week 16)
|
|
Global and US-specific Outcome Measures: Percentage of Participants With Endoscopic Response at Maintenance Week 44 as Assessed by SES-CD
Tidsramme: Maintenance Week 44 (Study Week 52)
|
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing.
Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum.
Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity.
Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
|
Maintenance Week 44 (Study Week 52)
|
|
US-specific Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 44
Tidsramme: Maintenance Week 44 (Study Week 52)
|
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations.
Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality).
For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10.
Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
|
Maintenance Week 44 (Study Week 52)
|
|
US-specific Outcome Measure: Percentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week 44
Tidsramme: Maintenance Period Week 44 (Study Week 52)
|
Corticosteroid-free remission was defined as PCDAI score of <=10 points and not receiving corticosteroids for at least 90 days prior to Week M-44.
The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations.
The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality.
For hematocrit and erythrocyte SR, the maximum score= 5.
For albumin level, the maximum score= 10.
All items were summed to derive the total score.
The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
|
Maintenance Period Week 44 (Study Week 52)
|
|
Global Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44 Who Had Clinical Remission at Induction Week 8
Tidsramme: Maintenance Week 44 (Study Week 52)
|
Clinical remission was defined as Pediatric Crohn's Disease Activity Index (PCDAI) score <=10.
The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations.
The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality.
For hematocrit and erythrocyte SR, the maximum score= 5.
For albumin level, the maximum score= 10.
All items were summed to derive the total score.
The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
|
Maintenance Week 44 (Study Week 52)
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Etterforskere
- Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
6. april 2021
Primær fullføring (Faktiske)
28. november 2024
Studiet fullført (Faktiske)
3. mars 2025
Datoer for studieregistrering
Først innsendt
14. desember 2020
Først innsendt som oppfylte QC-kriteriene
14. desember 2020
Først lagt ut (Faktiske)
17. desember 2020
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
30. juli 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
2. juli 2026
Sist bekreftet
1. juli 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Tarmsykdommer
- Sykdommer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Gastroenteritt
- Inflammatoriske tarmsykdommer
- Crohns sykdom
- Aminosyrer, peptider og proteiner
- Proteiner
- Antistoffer, monoklonalt, humanisert
- Antistoffer, monoklonalt
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Ustekinumab
Andre studie-ID-numre
- CR108864
- 2019-004225-24 (EudraCT-nummer)
- CNTO1275CRD3004 (Annen identifikator: Janssen Research & Development, LLC)
- 2023-504978-38-00 (Registeridentifikator: EUCT number)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
JA
IPD-planbeskrivelse
Datadelingspolicyen til Janssen Pharmaceutical Companies of Johnson & Johnson er tilgjengelig på www.janssen.com/clinical-trials/transparency.
Som nevnt på dette nettstedet, kan forespørsler om tilgang til studiedata sendes inn via Yale Open Data Access (YODA) prosjektnettsted på yoda.yale.edu
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Ja
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .